A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

Exclusion Criteria

• •Receipt of or need to continue to receive prohibited medications (listed in the protocol) more recently than the washout period (indicated in the protocol).
• •Surgery within 3 weeks prior to first study drug administration.
• •History within 5 years prior to first study drug administration of another malignancy except adequately treated Stage I/II basal/squamous cell skin cancer.
• •Radiation therapy to more than 25% of his/her total bone marrow during life.
• •Radiation therapy within 3 weeks prior to first study drug administration.
• •Known hypersensitivity to prednisone, docetaxel, polysorbate 80, lonafarnib, or any excipients associated with these medications.
• •Known contraindication to steroid use.
• •Known leptomeningeal or CNS metastasis.
• •Heart, vascular, or seizure disorder (detailed list in the protocol) within 6 months prior to first study drug administration.
• •Baseline QTc interval greater than 450 msec.
• •Grade 2 or more peripheral neuropathy or drug-related toxicity per CTCAE. Exceptions are noted in the protocol.
• •Any clinically significant condition or situation that the investigator thinks would interfere with the study evaluations or subject's participation.
• •Subject is part of staff personnel involved in the study.
• •Subject has known clinically significant immunosuppression.